The first biosimilars referencing Humira became available in 2023. That year, 10 FDA-approved adalimumab are now on the ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results